Disposition of 695750 shares by Jennifer Buell of Mink Therapeutics subject to Rule 16b-3
| INKT Stock | USD 9.32 0.34 3.52% |
Slightly above 62% of Mink Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Mink Therapeutics suggests that many traders are alarmed. Mink Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Mink Therapeutics' earnings reports, geopolitical events, and overall market trends.
Mink |
Filed transaction by Mink Therapeutics Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at finance.yahoo.com
 |
Mink Therapeutics Fundamental Analysis
We analyze Mink Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mink Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mink Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Mink Therapeutics is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Mink Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mink Therapeutics stock to make a market-neutral strategy. Peer analysis of Mink Therapeutics could also be used in its relative valuation, which is a method of valuing Mink Therapeutics by comparing valuation metrics with similar companies.
Peers
Mink Therapeutics Related Equities
| AFMD | Affimed NV | 5.00 | ||||
| ADAP | Adaptimmune Therapeutics | 3.51 | ||||
| DSGN | Design Therapeutics | 3.27 | ||||
| SGMO | Sangamo Therapeutics | 2.08 | ||||
| INZY | Inozyme Pharma | 1.68 | ||||
| TERN | Terns Pharmaceuticals | 1.35 | ||||
| CADL | Candel Therapeutics | 0.95 | ||||
| STOK | Stoke Therapeutics | 0.24 | ||||
| ALVR | Allovir | 0.10 | ||||
| FBRX | Forte Biosciences | 0.64 | ||||
| GLUE | Monte Rosa | 1.03 | ||||
| IKNA | Ikena Oncology | 2.14 | ||||
| ABOS | Acumen Pharmaceuticals | 2.99 | ||||
| HOWL | Werewolf Therapeutics | 4.48 | ||||
| XFOR | X4 Pharmaceuticals | 6.82 | ||||
| HOOK | Hookipa Pharma | 7.36 | ||||
| DAWN | Day One | 16.50 |
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.